论文部分内容阅读
目的观察吉非替尼联合适形放射治疗局部晚期非小细胞肺癌(NSCLC)的疗效及副反应。方法 40例局部晚期NSCLC患者随机分为吉非替尼联合适形放射治疗组(治疗组)和单纯适形放射治疗组(对照组)各20例。放疗采用6/15MV X线三维适形放射治疗,2.0~2.5 Gy次/,1次/d,5次/周,DT66~76 Gy。治疗组同步口服吉非替尼,从放疗第1天开始,连服2个月。结果治疗组与对照组有效率(CR+PR)分别为85.0%和60.0%(χ2=3.33,P>0.05);1,2年生存率分别为70.0%、35.0%和45.0%、20.0%(χ2=2.56,1.13,P>0.05)。吉非替尼组痤疮样皮疹发生率为55.0%,多为轻、中度,腹泻多为轻度。结论吉非替尼联合适形放射治疗局部晚期非小细胞肺癌的疗效较好,毒副反应较轻,可以耐受。
Objective To observe the efficacy and side effects of gefitinib combined with conformal radiotherapy in the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods Forty patients with locally advanced NSCLC were randomly divided into gefitinib combined with conformal radiotherapy group (treatment group) and pure conformal radiotherapy group (control group) 20 cases each. Radiotherapy using 6 / 15MV X-ray three-dimensional conformal radiotherapy, 2.0 ~ 2.5 Gy times /, 1 time / d, 5 times / week, DT66 ~ 76 Gy. The treatment group received gefitinib orally simultaneously, starting from the first day of radiotherapy, and continued for 2 months. Results The effective rates (CR + PR) of the treatment group and the control group were 85.0% and 60.0% respectively (χ2 = 3.33, P> 0.05). The 1 and 2 year survival rates were 70.0%, 35.0% and 45.0%, 20.0% χ2 = 2.56, 1.13, P> 0.05). Gefitinib group acne-like rash incidence was 55.0%, mostly mild to moderate, mostly mild diarrhea. Conclusion Gefitinib combined with conformal radiotherapy for locally advanced non-small cell lung cancer has better curative effect, less toxic and side effects, and can be tolerated.